Loading...
•
Sep 30, 2021
Quest Diagnostics Q3 2021 Earnings Report
Quest Diagnostics' financial performance in Q3 2021 decreased slightly compared to the previous year, but the company raised its outlook for the full year due to higher than anticipated COVID-19 testing volumes and base business performance.
Key Takeaways
Quest Diagnostics reported a slight decrease in revenue and earnings per share for the third quarter of 2021 compared to 2020. However, the company raised its full-year outlook due to higher than anticipated COVID-19 testing volumes and continued solid performance in its base business.
Third quarter revenues were $2.77 billion, a 0.4% decrease from 2020.
Reported diluted earnings per share (EPS) for the third quarter were $4.02, a 2.8% decrease from 2020; adjusted diluted EPS was $3.96, a 7.9% decrease from 2020.
Cash provided by operations year-to-date was $1.75 billion, a 19.6% increase from 2020.
The full-year 2021 outlook was raised to reflect higher than anticipated COVID-19 testing volumes and base business performance.
Quest Diagnostics
Quest Diagnostics
Forward Guidance
Quest Diagnostics updated its full year 2021 outlook, projecting net revenues between $10.45 billion and $10.60 billion, reported diluted EPS between $14.69 and $15.09, adjusted diluted EPS between $13.50 and $13.90, cash provided by operations of approximately $2.2 billion, and capital expenditures of approximately $400 million.
Positive Outlook
- Net revenues are projected to be between $10.45 billion and $10.60 billion.
- Net revenues increase is expected to be between 10.7% and 12.3%.
- Reported diluted EPS is projected to be between $14.69 and $15.09.
- Adjusted diluted EPS is projected to be between $13.50 and $13.90.
- Cash provided by operations is expected to be approximately $2.2 billion.